Director/PDMR Shareholding

Jul 3, 2013

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingDirector/PDMR Shareholding
RNS Number : 5437I
Advanced Medical Solutions Grp PLC
03 July 2013
 



3 July 2013

Advanced Medical Solutions Group plc (“AMS” or the “Company”)

Exercise of share options and Directors’ dealings

Advanced Medical Solutions Group plc (AIM:AMS), the global medical technology company, today announces that following the successful achievement of certain performance criteria, the following options from certain share incentive schemes have been exercised as outlined below.

In order to cover the exercise cost and the tax payable on this exercise Don Evans, Chairman, has sold Ordinary Shares of 5p each on 2 July 2013 as detailed below.

Long Term Incentive Plan (LTIP)  

Director

No. of LTIPs prior to exercise

LTIPs exercised

LTIPs after exercise

Don Evans, Chairman

256,713

256,713

–

Deferred Share Bonus Plan (DSB)

Director

No. of DSBs prior to exercise

DSBs exercised

DSBs after exercise

Don Evans, Chairman

128,587

124,176

4,411

The Company has also been informed that Pamela Evans, wife of Don Evans, Chairman, has sold 183,928 Ordinary Shares of 5p each at 74.13p per share.  As a result of these transactions Don Evans beneficial interest in the Company has increased from 3,162,587 shares to 3,188,511 shares.

Directors’ Dealings in shares

Director

Holding prior to exercise

Holding following exercise

Number of shares sold

Sale Price(p)

Resultant holding

% of issued share capital

Don Evans, Chairman

3,162,587

3,543,476

354,965

74.13p

3,188,511

1.5

The Company also announces that Christopher Meredith, Chief Executive Officer, purchased 2,023 Ordinary Shares of 5p each at 74.13p per share as part of the Deferred Share Bonus Plan.  Under the terms of the Plan, the shares will be held in trust on his behalf.

Following this transaction the beneficial ownership of Christopher Meredith is as follows:

Director

Date purchased

Shares Purchased

Resultant Holding

% of issued share capital

Christopher Meredith, CEO

2 July 2013

2,023

1,142,275

0.6

For further information:

Advanced Medical Solutions Group plc

Mary Tavener, Group Finance Director +44 (0) 1606 545 508

Investec (NOMAD)

Daniel Adams +44 (0) 20 7597 5970

END


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSBSGDRDBGBGXX

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.